GLP1R and type 2 diabetes mellitus: In contrast, the expense of orally administered harmine and other small molecule DYRK1A inhibitors is trivial in comparison, and GLP1R family drugs are already approved by regulatory agencies and in use in millions of people with T2D around the world.